Search | Clinical Trials Finder

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Acute Ischemic Stroke
Interventions: AB126 Neural Exosomes Intravenous Injection, AB126 Placebo; Biological · Other
Lead sponsor: Aruna Bio, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: S. hominis A 9 Product, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap; Drug · Other
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Ulcerative Colitis
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Little Rock, Arkansas • Lancaster, California • Rialto, California + 31 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSV-F Vaccine, Phosphate Buffer Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 1,330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more

Conditions: Influenza Infection
Interventions: VAX102 [Flagellin.HuM2e], Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Lenexa, Kansas • Galveston, Texas

Conditions: Perioral Rhytids, Aging, Wrinkle
Interventions: TEOSYAL RHA Redensity; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Monica, California • Coral Gables, Florida + 3 more

Conditions: Aging, Pain
Interventions: RHA®4 with new anesthetic agent, RHA®4-Lidocaine; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Beverly Hills, California • Coral Gables, Florida • Chicago, Illinois

Conditions: Influenza
Interventions: Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 31 more

Conditions: Spinal Cord Injuries
Interventions: Tests of sympathetic inhibition, Tests of above level sympathetic activation, Testing of below level sympathetic activation, Epidural stimulation, Transcutaneous stimulation; Diagnostic Test · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal], Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Daytona Beach, Florida • Miami, Florida • South Miami, Florida + 2 more

Conditions: Heart Failure
Interventions: Furoscix Infusor; Combination Product
Lead sponsor: scPharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Sylmar, California • Bridgeport, Connecticut • Tampa, Florida + 5 more

Conditions: Healthy
Interventions: Typhoid Vi Polysaccharide Vaccine, Placebo; Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Ad26.RSV.preF 5*10^10 vp, Ad26.RSV.preF 1*10^11 vp, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cholera Vaccination
Interventions: Vaxchora; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hereditary Angioedema
Interventions: CSL312, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more

Conditions: PDR
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: Up to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Shigella
Interventions: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Chronic Stress, Anxiety, Depression
Interventions: Building a Strong Identity and Coping Skills; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 11 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Harrisburg, Pennsylvania • Hershey, Pennsylvania • Spring Mills, Pennsylvania + 1 more

Conditions: Healthy Volunteer
Interventions: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer; Biological
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Irreversible Pulpitis (Toothache)
Interventions: buffered lidocaine, nonbuffered lidocaine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke

Targeted Investigation of Microbiome Elimination

Patient Experience Study of Deoxycholic Acid Injection

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

RHA Redensity - Perioral Rhytids

RHA® 4 With New Anesthetic - Nasolabial Folds

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury

A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults

Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

Cognitive, Emotional, and Neural Responses to Acute Inflammation

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

Blood Donor CVD 9000

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Confirmatory Efficacy of the Building a Strong Identity and Coping Skills Program

Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A

Effect of Buffered Numbing Solution on Patients With Toothaches